Compare DAC & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAC | CAPR |
|---|---|---|
| Founded | 1972 | 2005 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2006 | N/A |
| Metric | DAC | CAPR |
|---|---|---|
| Price | $101.00 | $24.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $105.00 | $41.38 |
| AVG Volume (30 Days) | 70.0K | ★ 1.3M |
| Earning Date | 02-09-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 25.05 | N/A |
| Revenue | ★ $1,034,370,000.00 | $11,130,509.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16,329.74 |
| P/E Ratio | $4.02 | ★ N/A |
| Revenue Growth | ★ 2.90 | N/A |
| 52 Week Low | $65.40 | $4.30 |
| 52 Week High | $102.20 | $40.37 |
| Indicator | DAC | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 66.00 | 49.58 |
| Support Level | $98.41 | $23.52 |
| Resistance Level | $101.72 | $25.70 |
| Average True Range (ATR) | 2.04 | 1.63 |
| MACD | 0.30 | -0.77 |
| Stochastic Oscillator | 90.52 | 15.86 |
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.